Literature DB >> 20233971

Mast cells and the neurofibroma microenvironment.

Karl Staser1, Feng-Chun Yang, D Wade Clapp.   

Abstract

Neurofibromatosis type 1 (NF1) is the most common genetic disorder with a predisposition to malignancy and affects 1 in 3500 persons worldwide. NF1 is caused by a mutation in the NF1 tumor suppressor gene that encodes the protein neurofibromin. Patients with NF1 have cutaneous, diffuse, and plexiform neurofibromas, tumors comprised primarily of Schwann cells, blood vessels, fibroblasts, and mast cells. Studies from human and murine models that closely recapitulate human plexiform neurofibroma formation indicate that tumorigenesis necessitates NF1 loss of heterozygosity in the Schwann cell. In addition, our most recent studies with bone marrow transplantation and pharmacologic experiments implicate haploinsufficiency of Nf1 (Nf1(+/-)) and c-kit signaling in the hematopoietic system as required and sufficient for tumor progression. Here, we review recent studies implicating the hematopoietic system in plexiform neurofibroma genesis, delineate the physiology of stem cell factor-dependent hematopoietic cells and their contribution to the neurofibroma microenvironment, and highlight the application of this research toward the first successful, targeted medical treatment of a patient with a nonresectable and debilitating neurofibroma. Finally, we emphasize the importance of the tumor microenvironment hypothesis, asserting that tumorigenic cells in the neurofibroma do not arise and grow in isolation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233971      PMCID: PMC2910605          DOI: 10.1182/blood-2009-09-242875

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  75 in total

1.  Physical mapping of the von Recklinghausen neurofibromatosis region on chromosome 17.

Authors:  J W Fountain; M R Wallace; A M Brereton; P O'Connell; R L White; D C Rich; D H Ledbetter; R J Leach; R E Fournier; A G Menon
Journal:  Am J Hum Genet       Date:  1989-01       Impact factor: 11.025

2.  The neurofibromatosis type 1 gene encodes a protein related to GAP.

Authors:  G F Xu; P O'Connell; D Viskochil; R Cawthon; M Robertson; M Culver; D Dunn; J Stevens; R Gesteland; R White
Journal:  Cell       Date:  1990-08-10       Impact factor: 41.582

Review 3.  The cellular functions of small GTP-binding proteins.

Authors:  A Hall
Journal:  Science       Date:  1990-08-10       Impact factor: 47.728

4.  The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase.

Authors:  J C Tan; K Nocka; P Ray; P Traktman; P Besmer
Journal:  Science       Date:  1990-01-12       Impact factor: 47.728

5.  Type 1 neurofibromatosis: selective expression of extracellular matrix genes by Schwann cells, perineurial cells, and fibroblasts in mixed cultures.

Authors:  S Jaakkola; J Peltonen; V Riccardi; M L Chu; J Uitto
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

6.  Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor.

Authors:  K M Zsebo; D A Williams; E N Geissler; V C Broudy; F H Martin; H L Atkins; R Y Hsu; N C Birkett; K H Okino; D C Murdock
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

7.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients.

Authors:  M R Wallace; D A Marchuk; L B Andersen; R Letcher; H M Odeh; A M Saulino; J W Fountain; A Brereton; J Nicholson; A L Mitchell
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

8.  Analysis of vascularity of human neurofibromas.

Authors:  J L Arbiser; E Flynn; R L Barnhill
Journal:  J Am Acad Dermatol       Date:  1998-06       Impact factor: 11.527

9.  Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W.

Authors:  K Nocka; J C Tan; E Chiu; T Y Chu; P Ray; P Traktman; P Besmer
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

10.  Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines.

Authors:  Y Y Zhang; T A Vik; J W Ryder; E F Srour; T Jacks; K Shannon; D W Clapp
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

View more
  36 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

2.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

3.  Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosis.

Authors:  Emiliano Trias; Mariángeles Kovacs; Peter H King; Ying Si; Yuri Kwon; Valentina Varela; Sofía Ibarburu; Ivan C Moura; Olivier Hermine; Joseph S Beckman; Luis Barbeito
Journal:  Glia       Date:  2019-12-20       Impact factor: 7.452

4.  Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT.

Authors:  Sabrina Brahimi-Adouane; Jean-Baptiste Bachet; Séverine Tabone-Eglinger; Frédéric Subra; Claude Capron; Jean-Yves Blay; Jean-François Emile
Journal:  Mol Oncol       Date:  2012-10-30       Impact factor: 6.603

Review 5.  Molecular and clinical aspects of drug-induced gingival overgrowth.

Authors:  P C Trackman; A Kantarci
Journal:  J Dent Res       Date:  2015-02-13       Impact factor: 6.116

6.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.

Authors:  Chung-Ping Liao; Reid C Booker; Jean-Philippe Brosseau; Zhiguo Chen; Juan Mo; Edem Tchegnon; Yong Wang; D Wade Clapp; Lu Q Le
Journal:  J Clin Invest       Date:  2018-05-21       Impact factor: 14.808

7.  Sustained activation of ERK1/2 MAPK in Schwann cells causes corneal neurofibroma.

Authors:  Paola Bargagna-Mohan; Akihiro Ishii; Ling Lei; Daniel Sheehy; Saagar Pandit; Grace Chan; Rashmi Bansal; Royce Mohan
Journal:  J Neurosci Res       Date:  2017-05-10       Impact factor: 4.164

8.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

Review 9.  Facial plexiform neurofibroma: is it truly just skin deep?

Authors:  Wenhui Huang; Wei-Sheng Chong
Journal:  BMJ Case Rep       Date:  2013-10-07

10.  Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.

Authors:  Beren Karaosmanoglu; Çetin Y Kocaefe; Figen Söylemezoğlu; Banu Anlar; Ali Varan; İbrahim Vargel; Sükriye Ayter
Journal:  Childs Nerv Syst       Date:  2018-02-17       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.